The Continuation Test: Five Operating Questions Before You Roll an Asset Into a Continuation Fund

We treat a continuation fund as what it is: a tool, not a verdict. The same vehicle that lets a genuinely strong company keep compounding under an owner who understands it can also let a tired one dodge the markdown it has already earned. Nothing in the structure tells you which case you are in. What tells you is whether there is a real, fundable next chapter for the business, and whether anyone has actually been put in charge of writing it. So we built a short test you can run before the term sheet rather than after the subpoena.

The Continuation Test: a continuation fund is an operating decision dressed as a financing decision. Pass all five questions and you are backing a thesis. Fail the first or the last and you are deferring a loss.

The continuation fund is an operating decision, not a liquidity decision

A continuation vehicle gets discussed as a financing manoeuvre: a way to hand existing investors their cash back while the firm holds on to an asset it likes. That framing is true and beside the point. The decision underneath it is operational. You are choosing to keep running a company you already own, for several more years, under your own management, on the argument that you can build something in the next hold that you did not build in the last one. Strip out the deal mechanics and that is the whole proposition. So the question that actually matters is not "can we structure a continuation fund?" The answer to that is almost always yes. The question is "is there a real next chapter for this business, and who is going to write it?" The five questions above are how we pull those two cases apart. They are deliberately blunt, because the structure is good at making a deferral look like a decision.

How a continuation fund actually works (90 seconds)

The mechanics are simpler than the debate around them. A firm takes one or more portfolio companies out of an ageing fund and moves them into a new vehicle it usually controls. The existing investors in the old fund are given a choice: cash out at the agreed price, or roll their stake into the new vehicle and keep riding. Fresh investors buy in alongside them. The old fund books an exit, the firm keeps operating the asset, and the clock resets.

One structural fact powers everything that follows. The firm is on both sides of the trade. It is the seller, acting for the old fund and its investors, and it is the buyer, acting for the new vehicle and its investors. It sets the price it sells at and the price it buys at, and they are the same price. That is not automatically a problem, but it is the reason a continuation fund carries questions a straight sale to an unrelated third party never does. Hold that fact; it is what makes questions three and four load-bearing.

Why they have exploded, and why the regulator is now looking

Continuation vehicles went from a niche workaround to a primary tool because the ordinary exits stopped working. Trade sales and flotations slowed, distributions back to investors thinned out, and a large backlog of unsold portfolio companies built up across the industry. By industry data the share of global private-equity exit value running through continuation routes rose from roughly 2.7% in 2020 to about 8.1% last year, with continuation funds making up the majority of around $106bn of GP-led secondary deals reported for the period, against a backlog of roughly 33,000 unsold portfolio companies. Read those figures as direction, not gospel; they are reported industry estimates, not our own, and the trend matters more than any single number.

That growth is why the regulator arrived. In 2026 the SEC's enforcement division opened a probe into private-equity continuation vehicles, focused on conflicts of interest, how assets are valued, and whether investors received sufficient and consistent disclosure. The concern is the structure itself: same party, both sides, setting the price. We are not characterising any firm or predicting any outcome. The point for an operator is narrower and more useful. The questions a regulator is now asking are the same questions a disciplined owner should have been asking anyway, and the next two years will reward the firms that were.

The Continuation Test, expanded

1. The Thesis Question. Is there a fresh, fundable value-creation plan, or are you re-wrapping the old one? A genuine continuation has a specific operating plan that the previous hold did not deliver: a new platform to build, a fresh, fundable value-creation plan, a buy-and-build runway, a margin programme that is scoped and staffed rather than slideware. If the next thesis is the last thesis with the dates moved, you are extending, not continuing. Extending can be defensible, but call it what it is, because the people who buy in next are buying the plan, not the logo.

2. The Operator Question. Who actually runs the next chapter, and are they incentivised for it? This is the question most often skipped and the one that most reliably predicts whether the second hold works. A continuation with the same operating bench and the same untouched incentive package is a markdown deferral with a management fee attached. A real one comes with a refreshed team and a reset package that pays out only if the new plan lands. This is the territory of the operating-partner model and of reset operator incentives; firms that bring a genuine operator to the next chapter, embedded growth-operator firms such as Claymore Partners are one example of the category, are answering this question rather than ducking it. The test is not whether an operator is named in the deck. It is whether that operator is paid to deliver the chapter and would walk if it were not real.

3. The Valuation-Defensibility Question. Could you defend the mark to a sceptical regulator, not just a friendly LP? The 2026 probe makes this concrete. A mark that survives only in a room of people who want it to survive will not survive the room that does not. The working test is adversarial: imagine the least sympathetic competent reader you can, hand them your valuation and your comparables, and ask whether it still stands. If it needs goodwill to hold, it is not a valuation, it is a hope with a number on it.

4. The Disclosure-Symmetry Question. Do the rolling investors and the incoming buyers see the same information? The conflict here is structural, not hypothetical: one party, both sides of the trade. Symmetric disclosure, the same financials, the same risks, the same outlook to everyone, is the single cleanest thing that separates a defensible continuation from a problem waiting for a subpoena. If the rolling investors and the new buyers are working from different decks, the structure has already failed the test, whatever the price says.

5. The Honest-Alternative Question. If a third party offered this exact price today, would you sell? This is the question that makes the other four honest. If a clean, unrelated buyer put the continuation price on the table this morning, and you would take it, then the price is real and the continuation is a choice to keep compounding rather than a way to avoid a number. If you would not sell at that price to a stranger, you are not valuing the asset, you are repricing the bag. The gap between the price you would accept from an outsider and the price you are rolling at is the size of the problem.

Reading your score: when a continuation fund is the right call, and when it is not

Five clean passes is a real next chapter. There is a fundable plan, an incentivised team to run it, a mark you could defend to a hostile reader, symmetric disclosure, and a price you would accept from a stranger. Back it; this is the case the tool was built for, and it is genuinely good for a strong asset and the people who own it.

A fail on the Thesis Question or the Honest-Alternative Question is the one to take seriously. Those two are the load test. Fail either and you are most likely deferring a loss, and the regulator, the rolling investors and the incoming buyers will all eventually price what you postponed. A fail on the Operator Question is the quiet one: the deal can look fine on paper and still not work, because nobody was actually put in charge of the next chapter. If you only have time to ask two of the five, ask the first and the last. If you have time for a third, ask who runs it.

Continuation fund versus a straight sale versus a NAV loan

It helps to set the three liquidity tools side by side, because they are often weighed against each other in the same meeting. A straight sale moves the asset to an unrelated buyer, sets a clean market price, and ends your involvement; it is the honest benchmark the fifth question leans on. A continuation fund moves the asset into a new vehicle you usually control, brings in new investors, and sets a price you sit on both sides of; ownership changes hands but the operator does not. A NAV loan borrows against the value of the fund's portfolio without selling anything, so no asset moves and no price is struck; it adds leverage in place of an exit. All three buy time in a slow market. None of them removes risk; they relocate it. The continuation fund is the only one of the three that asks you to value your own asset to yourself, which is exactly why it needs a test.

Frequently asked questions

What is a continuation fund in private equity?
A continuation fund is a new vehicle a private equity firm uses to move one or more portfolio companies out of an ageing fund and into a new one it usually controls. Existing investors can cash out or roll their stake over, and new investors buy in. Because the firm sits on both sides of the deal, seller for the old fund, buyer for the new one, continuation funds raise questions about valuation and disclosure that a straight sale does not.

When does a continuation fund make sense?
A continuation fund makes sense when there is a genuine, fundable next chapter for the asset: a specific value-creation plan the previous hold did not deliver, an operator team incentivised to run it, and a valuation a sceptical outsider could defend. It is the wrong tool when it is used to avoid marking down or selling an asset that has simply run out of thesis.

Are continuation funds a red flag?
Not on their own. A continuation fund is a neutral tool. The red flags are specific: no fresh operating plan, no refreshed management incentives, a valuation that only holds among friendly investors, and rolling and incoming investors seeing different information. A continuation fund that passes those tests is defensible; one that fails them is a deferred markdown.

Why is the SEC investigating continuation funds?
In 2026 the SEC's enforcement division opened a probe into private equity continuation vehicles, focused on conflicts of interest, how assets are valued, and whether investors received sufficient and consistent disclosures. The concern flows from the structure: the firm acts as both seller and buyer, which creates an incentive to value the asset favourably and a risk that the two sides do not receive the same information.

What is the difference between a continuation fund and a NAV loan?
A continuation fund moves an asset into a new vehicle and brings in new investors to provide liquidity; ownership changes hands and a price has to be set. A NAV loan borrows against the value of a fund's portfolio without selling anything, so no asset moves and no price is struck, it adds leverage instead. Both are liquidity tools for a slow exit market, and both shift risk rather than removing it.